Joseph Maakaron, MD, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in patients with DLBCL.
Joseph Maakaron, MD
Advertisement
Articles by Joseph Maakaron, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
3
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
4
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
5